CME in the 13F filings
Cme Group Inc · CUSIP 12572Q105
- Quarter end
- 31 Dec 2023
- the date the book describes
- Filed
- 5 Nov 2026
- latest of these filings; the earliest 8 Feb 2024
- Managers listing it
- 32
- at least, of 95 tracked, among listed positions
- Comparable managers
- 93
- filed both Q3 2023 and Q4 2023; 28 listed it in both
- Shares listed
- 48,616,445
- combined, among listed positions
- Reported value
- $10.2bn
- combined, at the quarter end
Among the 93 comparable managers: 18 buyers (opened or added shares) and 14 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing CME in Q4 2023
32 of 32 holders
Largest increases and reductions, by shares
Increases
- Capital World Investorsexisting position · 14,589,867 shares now+1,172,575
- T. Rowe Price Associates Incexisting position · 3,615,243 shares now+1,048,511
- Fidelity (FMR LLC)existing position · 4,964,441 shares now+934,670
- Arrowstreet Capital LPexisting position · 1,220,097 shares now+756,633
- AQR Capital Management LLCexisting position · 864,719 shares now+180,585
Reductions
- Capital Research Global Investorsexisting position · 6,591,306 shares now-2,412,913
- Invesco Ltdexisting position · 3,105,772 shares now-359,650
- D. E. Shaw & Co.existing position · 407,021 shares now-353,211
- Neuberger Berman Group LLCexisting position · 3,437,358 shares now-349,994
- Two Sigma Advisers LPexisting position · 680,100 shares now-271,300
New positions and exits
New (2)
Exited (2)
- Brevan Howard Capital Management LPwas $21m
- Maverick Capital Ltdwas $628k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2013 | 23 | $5.0bn | n.a. | n.a. |
| Q3 2013 | 21 | $5.0bn | n.a. | n.a. |
| Q4 2013 | 19 | $4.5bn | n.a. | n.a. |
| Q1 2014 | 18 | $4.2bn | n.a. | n.a. |
| Q2 2014 | 19 | $4.2bn | n.a. | n.a. |
| Q3 2014 | 18 | $5.1bn | n.a. | n.a. |
| Q4 2014 | 19 | $5.6bn | n.a. | n.a. |
| Q1 2015 | 22 | $5.8bn | n.a. | n.a. |
| Q2 2015 | 22 | $5.5bn | n.a. | n.a. |
| Q3 2015 | 25 | $5.2bn | n.a. | n.a. |
| Q4 2015 | 24 | $4.9bn | n.a. | n.a. |
| Q1 2016 | 26 | $5.4bn | n.a. | n.a. |
| Q2 2016 | 29 | $6.0bn | n.a. | n.a. |
| Q3 2016 | 27 | $5.8bn | n.a. | n.a. |
| Q4 2016 | 30 | $6.3bn | n.a. | n.a. |
| Q1 2017 | 30 | $6.4bn | n.a. | n.a. |
| Q2 2017 | 35 | $7.0bn | n.a. | n.a. |
| Q3 2017 | 31 | $7.7bn | n.a. | n.a. |
| Q4 2017 | 30 | $7.8bn | n.a. | n.a. |
| Q1 2018 | 33 | $8.8bn | n.a. | n.a. |
| Q2 2018 | 32 | $9.9bn | n.a. | n.a. |
| Q3 2018 | 30 | $10.5bn | n.a. | n.a. |
| Q4 2018 | 27 | $12.4bn | n.a. | n.a. |
| Q1 2019 | 31 | $12.0bn | n.a. | n.a. |
| Q2 2019 | 28 | $14.6bn | n.a. | n.a. |
| Q3 2019 | 29 | $16.0bn | n.a. | n.a. |
| Q4 2019 | 28 | $15.3bn | n.a. | n.a. |
| Q1 2020 | 32 | $13.4bn | n.a. | n.a. |
| Q2 2020 | 32 | $12.2bn | n.a. | n.a. |
| Q3 2020 | 32 | $11.8bn | n.a. | n.a. |
| Q4 2020 | 26 | $11.4bn | n.a. | n.a. |
| Q1 2021 | 26 | $12.3bn | n.a. | n.a. |
| Q2 2021 | 26 | $12.8bn | n.a. | n.a. |
| Q3 2021 | 30 | $11.6bn | n.a. | n.a. |
| Q4 2021 | 26 | $14.6bn | n.a. | n.a. |
| Q1 2022 | 32 | $15.8bn | n.a. | n.a. |
| Q2 2022 | 37 | $13.4bn | n.a. | n.a. |
| Q3 2022 | 38 | $10.9bn | n.a. | n.a. |
| Q4 2022 | 36 | $9.1bn | n.a. | n.a. |
| Q1 2023 | 32 | $9.6bn | n.a. | n.a. |
| Q2 2023 | 34 | $9.5bn | n.a. | n.a. |
| Q3 2023 | 33 | $9.8bn | n.a. | n.a. |
| Q4 2023 | 32 | $10.2bn | 18 | 14 |
| Q1 2024 | 30 | $8.9bn | 13 | 16 |
| Q2 2024 | 33 | $8.3bn | 20 | 11 |
| Q3 2024 | 35 | $10.0bn | 22 | 12 |
| Q4 2024 | 35 | $11.1bn | 16 | 15 |
| Q1 2025 | 35 | $12.1bn | 21 | 13 |
| Q2 2025 | 37 | $12.7bn | 18 | 17 |
| Q3 2025 | 33 | $11.9bn | 14 | 17 |
| Q4 2025 | 31 | $11.1bn | 20 | 26 |
| Q1 2026 | 33 | $11.4bn | 15 | 26 |
| Q2 2026 | 37 | $9.3bn | 31 | 13 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
CME and V →CME and AXP →CME and BAC →Choose a stock to compare with CME →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own CME, latest filings →Back to the 13F Explorer →